Fimea to arrange a Horizon Scanning event for pharmaceutical companies on 10 April 2018
The event provides pharmaceutical companies with an opportunity to present new hospital-only medicines to Fimea’s HTA team. The event is intended for the presentation of medicinal products that will potentially be assessed by Fimea as part of the HTA process for hospital-only medicines during 2018–2019.
Fimea hopes that the event will be primarily attended by companies that are expecting a favourable opinion from European Medicines Agency (EMA) for a new hospital-only medicinal product or for a significant extension of the therapeutic indication of a product already on the market during the period of April 2018 to June 2019.
Those interested in attending the event are kindly requested to register by e-mail (pia.blomqvist(at)fimea.fi) by 9 February 2018. When registering, please designate tentatively the persons who will participate in the consultation and the products the presentation pertains to. After registration, companies will be asked to provide a brief advance description of the products to be introduced prior to the event.
The event will be arranged in Helsinki on 10 April 2018 starting from 9.00 am. The more specific venue details and the times reserved for each company will be announced later to the companies attending the event. If there are more registrations than there are times reserves for consultations (8 consultations), the most topical products in view of the assessment of hospital-only medicines will be selected for the consultations. The duration of the presentation may not exceed 25 minutes per company. The language of the presentation and the materials may be Finnish or English.
- Piia Rannanheimo, Pharmacoeconomist, tel. +358 29 522 3517
- Vesa Kiviniemi, Head of Assessment, tel. +358 29 522 3516
- Email address format: firstname.lastname@example.org